News

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial
Key Takeaways Sarepta Therapeutics shares were down nearly 25% early Friday morning.The tumble followed a report that a third ...
Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta's Setback Deepens With Another Gene Therapy Fatality
Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...
Fierce Biotech2h
3rd patient dies after receiving a Sarepta gene therapy
While the previous two deaths occurred in patients treated with Elevidys, the most recent patient was receiving one of ...
Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring
Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta Therapeutics saw its share prices rise by 19.53 percent on Thursday to close at ...
The Malaysian Reserve6h
SRPT INVESTOR DEADLINE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
If you suffered substantial losses and wish to serve as lead plaintiff of the Sarepta class action lawsuit, please provide ...
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Hosted on MSN1m
Sarepta Didn’t Tell Investors About a Patient Death. Wall Street is Furious.
Wall Street was fuming at Sarepta Therapeutics on Friday ... patients have died this year after receiving its Duchenne ...
Southwest Journal5h
Breaking: Second Patient Death Prompts FDA Investigation of Sarepta’s Elevidys Gene Therapy
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
Patient dies in Sarepta gene therapy trial, adding to safety concerns
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
Sarepta shares slump after reports of third patient death this year
Shares of Sarepta Therapeutics declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it the third such ...
Sarepta shares slump after report of third patient death this year
Shares of Sarepta Therapeutics declined 16.5% in premarket trading on Friday after a Bloomberg report that a trial patient who received an experimental gene therapy has died from liver failure, making ...